Physicochemical Properties
| Molecular Formula | C20H32O4 |
| Molecular Weight | 336.47 |
| Exact Mass | 336.23 |
| CAS # | 35536-53-9 |
| PubChem CID | 5283062 |
| Appearance | White to off-white solid powder |
| Density | 1.1±0.1 g/cm3 |
| Boiling Point | 510.3±45.0 °C at 760 mmHg |
| Flash Point | 276.5±25.2 °C |
| Vapour Pressure | 0.0±3.0 mmHg at 25°C |
| Index of Refraction | 1.543 |
| LogP | 3.41 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 12 |
| Heavy Atom Count | 24 |
| Complexity | 439 |
| Defined Atom Stereocenter Count | 3 |
| SMILES | CCCCC[C@@H](/C=C/[C@H]1CCC(=O)[C@@H]1C/C=C\CCCC(=O)O)O |
| InChi Key | CTHZICXYLKQMKI-FOSBLDSVSA-N |
| InChi Code | InChI=1S/C20H32O4/c1-2-3-6-9-17(21)14-12-16-13-15-19(22)18(16)10-7-4-5-8-11-20(23)24/h4,7,12,14,16-18,21H,2-3,5-6,8-11,13,15H2,1H3,(H,23,24)/b7-4-,14-12+/t16-,17-,18+/m0/s1 |
| Chemical Name | (Z)-7-[(1R,2R)-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid |
| Synonyms | 11-deoxy-PGE2; 35536-53-9; (Z)-7-[(1R,2R)-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; 11-deoxy-Prostaglandin E2; 9-oxo-15S-hydroxy-5Z,13E-prostadienoic acid; 11-Deoxyprostaglandin E2; (Z)-7-((1R,2R)-2-((E,3S)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid; Prosta-5,13-dien-1-oic acid, 15-hydroxy-9-oxo-, (5Z,13E,15S)-; |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets |
Binds to human EP1 prostanoid receptor (Ki = 2.3 μM in competitive binding assay). [2] 11-Deoxy Prostaglandin E2 binds to human EP1 prostanoid receptor (Ki not specified) and interacts with EP4 receptor based on homology modeling studies. |
| ln Vitro |
11-Deoxy Prostaglandin E2 exhibited partial agonist activity at human EP1 receptor:
- Induced intracellular Ca²⁺ mobilization with EC₅₀ = 3.1 μM (fluorometric assay)
- Binding affinity 7-fold lower than native PGE2 (Ki = 0.3 μM vs. 2.3 μM) [2] |
| References |
[1]. Improved homology modeling of the human & rat EP4 prostanoid receptors. BMC Mol Cell Biol. 2019 Aug 27;20(1):37. [2]. Key structural features of prostaglandin E(2) and prostanoid analogs involved in binding and activation of the human EP(1) prostanoid receptor. Mol Pharmacol. 2001 Jun;59(6):1446-56. |
| Additional Infomation |
11-Deoxy Prostaglandin E2 is a PGE2 analog lacking the 11-hydroxyl group. Structural modeling reveals this modification reduces hydrogen bonding capacity with Arg³¹⁰ residue in EP1 receptor binding pocket, explaining its lower affinity compared to PGE2. Serves as a tool compound for studying prostanoid receptor structure-activity relationships. [1][2] 11-Deoxy-PGE2 is a prostanoid. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9720 mL | 14.8602 mL | 29.7203 mL | |
| 5 mM | 0.5944 mL | 2.9720 mL | 5.9441 mL | |
| 10 mM | 0.2972 mL | 1.4860 mL | 2.9720 mL |